A sensitive, real-time, RNA-specific PCR method for the detection of recombinant AAV-CFTR vector expression.

Area of Science:

• Molecular Biology
• Gene Therapy
• Biotechnology

Background:

• Adeno-associated virus (AAV) vectors are widely used in gene therapy, but their DNA can contaminate RNA samples.
• This DNA contamination interferes with traditional reverse transcriptase-polymerase chain reaction (RT-PCR) assays, hindering accurate mRNA detection.
• Existing methods like DNase I treatment are often insufficient to remove single-stranded AAV DNA.

Purpose of the Study:

• To develop a sensitive and reliable real-time RNA-Specific reverse transcriptase PCR (RS-PCR) method for detecting vector-derived mRNA.
• To overcome the challenge of AAV DNA contamination in RNA preparations.
• To provide a DNase I-independent method for accurate gene expression analysis in AAV-mediated gene therapy.

Main Methods:

• Developed a real-time RS-PCR assay utilizing a linker sequence (X) incorporated into the cDNA template.
• Employed primers targeting AAV vector sequences and the X-primer site.
• Utilized a vector-specific Taqman probe for sensitive, real-time detection.
• Proposed endogenous control strategies using beta-glucuronidase and cystic fibrosis transmembrane conductance regulator (CFTR) expression.

Main Results:

• Validated the sensitivity and RNA specificity of the novel RS-PCR method.
• Demonstrated successful detection of recombinant AAV-CFTR expression in an in vitro transduction assay.
• Showcased the method's applicability for preclinical and clinical trial sample analysis.

Conclusions:

• The developed RS-PCR method offers a robust solution for accurate mRNA detection in AAV gene therapy.
• This technique enhances the reliability of gene expression analysis, crucial for therapeutic development.
• The RS-PCR method supports the advancement of AAV-based gene therapies from research to clinical application.